StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.
Oragenics Stock Performance
Shares of NYSE OGEN opened at $1.03 on Wednesday. The firm has a market cap of $4.62 million, a PE ratio of -0.11 and a beta of 0.31. Oragenics has a 52 week low of $1.01 and a 52 week high of $7.74. The company has a 50-day simple moving average of $1.73.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings data on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Stocks Leading the U.S. Agriculture Comeback
- There Are Different Types of Stock To Invest In
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Comparing and Trading High PE Ratio Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
